Red Clover Menopause Randomized Trial: What the Evidence Says

Quick Answer

Red Clover Menopause Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Menopause, the permanent cessation of menstruation due to declining estrogen and progesterone levels, typically occurs between ages 50 and 52 and is associated with physical and psychological symptoms that can impair health-related quality of life (QoL). [Jarrín-Orozco María P. (2025); evidence level 2]
• Adding to this complexity, up to 12 possible combinations of these metabotypes, termed metabotype clusters (MCs), can occur when consuming isoflavones, resveratrol, and ellagic acid, as a result of the combination of the individual metabotypes (e.g., UMA+EP+LP, UMB+ENP+LP, etc.). [Jarrín-Orozco María P. (2025); evidence level 2]
• Hulteen et al., 2023 Davis and Baber, 2022 Zhu et al., 2020 The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel, 2022 Newson, 2016 Depypere et al., 2016 Franco et al., 2016 Estrogen deficiency after menopause accelerates chronic disease risk and diminishes quality of life. [Bolgova Olena (2025); evidence level 4]
• Epidemiological data demonstrate that women experiencing severe vasomotor symptoms have a 1.5-fold increased risk of coronary heart disease and stroke compared to asymptomatic women. [Bolgova Olena (2025); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For red clover menopause randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Jarrín-Orozco María P. (2025). Polyphenol-Related Gut Metabotype Signatures Linked to Quality of Life in Postmenopausal Women: A Randomized, Placebo-Controlled Crossover Trial. DOI: 10.3390/nu17223572. PMCID: PMC12655133. PMID: 41305622. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12655133/
• Bolgova Olena (2025). Natural strategies to optimize estrogen levels in aging women: mini review. DOI: 10.3389/fragi.2025.1706117. PMCID: PMC12685915. PMID: 41377590. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12685915/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.